SCHEMBL12879720

SCHEMBL12879720

Cc1cccc(N2CCC(N3CCOCC3)CC2)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
KDM4E B2RXH2 1/20 0.52
L3MBTL3 Q96JM7 4/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
MBTD1 Q05BQ5 2/20 0.51
AOC3 Q16853 2/20 0.51
ADRB1 P08588 1/20 0.50
MAPT P10636 1/20 0.49
PKM P14618 1/20 0.49
MAPK1 P28482 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
NOTUM Q6P988 1/20 0.48
TP53BP1 Q12888 1/20 0.47
KCNH2 Q12809 2/20 0.46
HRH3 Q9Y5N1 1/20 0.45
TRPV6 Q9H1D0 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19710874 0.92 NOTUM (0.52) ALDH1A1KDM4EL3MBTL3L3MBTL1MBTD1
SCHEMBL14528861 0.86 L3MBTL3 (0.65) ALDH1A1L3MBTL3L3MBTL1MBTD1ADRB1
SCHEMBL12980 0.84 ADRB1 (0.62) ALDH1A1KDM4EADRB1MAPTPKM
SCHEMBL24774008 0.84 ALDH1A1 (0.59) ALDH1A1L3MBTL3L3MBTL1MBTD1ADRB1
SCHEMBL521012 0.84 AOC3 (0.55) ALDH1A1L3MBTL3L3MBTL1MBTD1AOC3
SCHEMBL171780 0.83 TRPV6 (0.60) ALDH1A1ADRB1MAPTNOTUMKCNH2
SCHEMBL12082369 0.83 L3MBTL3 (0.59) ALDH1A1KDM4EL3MBTL3L3MBTL1MBTD1
SCHEMBL104159 0.82 L3MBTL3 (0.73) ALDH1A1KDM4EL3MBTL3L3MBTL1MBTD1
SCHEMBL14528639 0.82 L3MBTL3 (0.59) ALDH1A1L3MBTL3L3MBTL1MBTD1ADRB1
SCHEMBL2634916 0.82 L3MBTL3 (0.51) ALDH1A1L3MBTL3L3MBTL1MBTD1AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3209664-B1 BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-06-03 EP disclosed
US-20170355707-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-12-14 US disclosed
US-7884098-B2 2-{[5-Fluoro-2-({3-[2-(4-morpholinyl)ethyl]phenyl}amino)-4-pyrimidinyl]amino}-N-(2-hydroxyethyl)benzamide, useful in the treatment of cancer GLAXOSMITHKLINE LLC (US) 2011-02-08 US disclosed
US-20100016318-A1 ANTHRANILAMIDE INHIBITORS OF AURORA KINASE SMITHKLINE BEECHAM CORPORATION (US) 2010-01-21 US disclosed
US-7625903-B2 Anticancer agent; N-(1-methylethyl)-2-[(5-methyl-2-{[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino}-4-pyrimidinyl)amino]benzamide SMITHKLINE BEECHAM CORPORATION (US) 2009-12-01 US disclosed
US-20080182852-A1 ANTHRANILAMIDE INHIBITORS OF AURORA KINASE GLAXOSMITHKLINE LLC 2008-07-31 US disclosed
WO-2008092049-A1 ANTHRANILAMIDE INHIBITORS OF AURORA KINASE SMITHKLINE BEECHAM CORPORATION (US) 2008-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182852-A1 ANTHRANILAMIDE INHIBITORS OF AURORA KINASE AURKA, AURKC, AURKB ALDH1A1 3182/4885KDM4E 775/4885L3MBTL3 2288/4885
US-20170355707-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS PIK3R3, JAK2, JAK3 ALDH1A1 3131/4885KDM4E 2233/4885L3MBTL3 2467/4885
US-20100016318-A1 ANTHRANILAMIDE INHIBITORS OF AURORA KINASE AURKA, AURKC, AURKB ALDH1A1 2849/4885KDM4E 790/4885L3MBTL3 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.